[Pharmacological, pharmacokinetic and clinical profiles of Difelikefalin (KORSUVA IV Injection Syringe for Dialysis), a peripheral kappa opioid receptor agonist].

Difelikefalin (KORSUVA IV Injection Syringe for Dialysis) is a novel kappa opioid receptor (KOR) agonist. In September 2023, difelikefalin was approved for the treatment of pruritus in hemodialysis patients. Pruritus is a major symptom that significantly reduces the quality of life of hemodialysis patients, even with improved dialysis techniques, dialysis membranes, and dialysate solutions.